Effect of ciclesonide on bronchial asthma in athletes.
BACKGROUND
Although it is well established that the incidence of bronchial asthma is higher in the athlete population than in the general population, little information exists about the efficacy of treatment of bronchial asthma in the athlete population.


OBJECTIVE
We conducted this study with the objective of determining the efficacy of treatment of bronchial asthma in an athlete population living in Niigata Prefecture, Japan.


METHODS
We conducted a retrospective study of bronchial asthma in an athlete population. Athletes diagnosed as having asthma, based on the Global Initiatives for Asthma (GINA) guidelines, who visited the Niigata Institute for Health and Sports Medicine between January 2007 and June 2008 were enrolled in this study. We compared two groups of patients, a group treated with ciclesonide (CIC) alone and another treated with montelukast alone, with the treatment duration lasting at least 3 months in both groups. The CIC or montelukast groups were compared in terms of the clinical symptoms, pulmonary function parameters, and fraction of exhaled nitric oxide (FENO).


RESULTS
There were no significant differences in the sex distribution, age, frequency of symptoms, pulmonary function parameters, or other examination data before treatment between the CIC and montelukast groups. The CIC group tended to show better symptom control and to need fewer changes of treatment than the montelukast group. While improvements of the pulmonary function parameters and FENO values were observed in the CIC group, no significant changes of these parameters were observed in the montelukast group.


CONCLUSIONS
These data suggest that CIC offers greater promise for the control of asthma than montelukast in the athlete population, although further investigation is required.
Koya
Toshiyuki
T
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Course in Biological Functions and Medical Control, Niigata University, Graduate School of Medical and Dental Sciences, Niigata City, Niigata, Japan. tkoya@med.niigata-u.ac.jp
Hasegawa
Takashi
T
Tanaka
Junta
J
Kawakami
Hidenori
H
Hayashi
Masachika
M
Kagamu
Hiroshi
H
Narita
Ichiei
I
Arakawa
Masaaki
M
Suzuki
Eiichi
E
D000085:Acetates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000293:Adolescent; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D056352:Athletes; D001944:Breath Tests; D003521:Cyclopropanes; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008450:Maximal Midexpiratory Flow Rate / Q000187:drug effects / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D013440:Sulfides; D016896:Treatment Outcome; D014797:Vital Capacity / Q000187:drug effects / Q000502:physiology; D055815:Young Adult
D000085:Acetates; D003521:Cyclopropanes; D011282:Pregnenediones; D011804:Quinolines; D013440:Sulfides; D009569:Nitric Oxide; C093875:montelukast; C120481:ciclesonide